These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 22998750)

  • 41. Islets in type 2 diabetes: in honor of Dr. Robert C. Turner.
    Bonner-Weir S; O'Brien TD
    Diabetes; 2008 Nov; 57(11):2899-904. PubMed ID: 18971437
    [No Abstract]   [Full Text] [Related]  

  • 42. Is type 2 diabetes an amyloidosis and does it really matter (to patients)?
    Cooper GJ; Aitken JF; Zhang S
    Diabetologia; 2010 Jun; 53(6):1011-6. PubMed ID: 20229094
    [No Abstract]   [Full Text] [Related]  

  • 43. Tyrosine kinase inhibitors in systemic sclerosis: the case for imatinib.
    Castelino FV; Bhattacharyya S; Varga J
    Curr Rheumatol Rep; 2009 Jul; 11(3):161-3. PubMed ID: 19604458
    [No Abstract]   [Full Text] [Related]  

  • 44. Synergistic Effects of Milk-Derived Exosomes and Galactose on
    Melnik BC
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33494388
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibition of c-Kit is not required for reversal of hyperglycemia by imatinib in NOD mice.
    Lau J; Zhou Q; Sutton SE; Herman AE; Schmedt C; Glynne R
    PLoS One; 2014; 9(1):e84900. PubMed ID: 24454763
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Amelioration of diabetes by imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and anti-apoptotic preconditioning.
    Hägerkvist R; Sandler S; Mokhtari D; Welsh N
    FASEB J; 2007 Feb; 21(2):618-28. PubMed ID: 17135364
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Imatinib mesylate (Gleevec) protects against streptozotocin-induced diabetes and islet cell death in vitro.
    Hägerkvist R; Makeeva N; Elliman S; Welsh N
    Cell Biol Int; 2006 Dec; 30(12):1013-7. PubMed ID: 17020808
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Islet amyloid and type 2 diabetes mellitus.
    Höppener JW; Ahrén B; Lips CJ
    N Engl J Med; 2000 Aug; 343(6):411-9. PubMed ID: 10933741
    [No Abstract]   [Full Text] [Related]  

  • 49. Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes.
    Mokhtari D; Welsh N
    Clin Sci (Lond); 2009 Nov; 118(4):241-7. PubMed ID: 19886867
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Does the small tyrosine kinase inhibitor Imatinib mesylate counteract diabetes by affecting pancreatic islet amyloidosis and fibrosis?
    Welsh N
    Expert Opin Investig Drugs; 2012 Nov; 21(11):1743-50. PubMed ID: 22998750
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Are off-target effects of imatinib the key to improving beta-cell function in diabetes?
    Welsh N
    Ups J Med Sci; 2022; 127():. PubMed ID: 36187072
    [TBL] [Abstract][Full Text] [Related]  

  • 52.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 53.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 54.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.